Metabotropic glutamate receptors

T. Knopfel, D. Madge, F. Nicoletti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Metabotropic glutamate (mGlu) receptors are becoming increasingly interesting as potential drug targets for the treatment of a variety of central nervous system (CNS) disorders including epilepsy and chronic and acute neurodegeneration. In contrast to the ionotropic glutamate (iGlu) receptors of the N-methyl-D-aspartate (NMDA), 2-amino-3-[5-methyl-3-hydroxyisoxazol-4-yl]propionic acid (AMPA) and kainate types that form ion channels, mGlu receptors couple to G-proteins and modulate a variety of membrane enzymes and ion channels. The eight mGlu receptor subtypes revealed to date by molecular cloning exhibit not only distinct pharmacological properties, but also different functions in the brain. This article describes the potential disease targets of compounds acting at the various mGlu receptor subtypes, and the development of such compounds by reviewing both the primary and patent literature.

Original languageEnglish
Pages (from-to)1061-1067
Number of pages7
JournalExpert Opinion on Therapeutic Patents
Volume6
Issue number10
Publication statusPublished - 1996

Fingerprint

epilepsy
Metabotropic Glutamate Receptors
patent
brain
Ion Channels
drug
Disease
Literature
Ionotropic Glutamate Receptors
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Patents
Kainic Acid
Central Nervous System Diseases
Molecular Cloning
N-Methylaspartate
GTP-Binding Proteins
Epilepsy
Pharmacology
literature
Brain

Keywords

  • central nervous system
  • epilepsy
  • G-protein coupled receptors
  • metabotropic glutamate receptors
  • neurodegeneration
  • stroke

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law

Cite this

Metabotropic glutamate receptors. / Knopfel, T.; Madge, D.; Nicoletti, F.

In: Expert Opinion on Therapeutic Patents, Vol. 6, No. 10, 1996, p. 1061-1067.

Research output: Contribution to journalArticle

Knopfel, T, Madge, D & Nicoletti, F 1996, 'Metabotropic glutamate receptors', Expert Opinion on Therapeutic Patents, vol. 6, no. 10, pp. 1061-1067.
Knopfel, T. ; Madge, D. ; Nicoletti, F. / Metabotropic glutamate receptors. In: Expert Opinion on Therapeutic Patents. 1996 ; Vol. 6, No. 10. pp. 1061-1067.
@article{488e289cb8ea40fcb39e240ed7b96c7f,
title = "Metabotropic glutamate receptors",
abstract = "Metabotropic glutamate (mGlu) receptors are becoming increasingly interesting as potential drug targets for the treatment of a variety of central nervous system (CNS) disorders including epilepsy and chronic and acute neurodegeneration. In contrast to the ionotropic glutamate (iGlu) receptors of the N-methyl-D-aspartate (NMDA), 2-amino-3-[5-methyl-3-hydroxyisoxazol-4-yl]propionic acid (AMPA) and kainate types that form ion channels, mGlu receptors couple to G-proteins and modulate a variety of membrane enzymes and ion channels. The eight mGlu receptor subtypes revealed to date by molecular cloning exhibit not only distinct pharmacological properties, but also different functions in the brain. This article describes the potential disease targets of compounds acting at the various mGlu receptor subtypes, and the development of such compounds by reviewing both the primary and patent literature.",
keywords = "central nervous system, epilepsy, G-protein coupled receptors, metabotropic glutamate receptors, neurodegeneration, stroke",
author = "T. Knopfel and D. Madge and F. Nicoletti",
year = "1996",
language = "English",
volume = "6",
pages = "1061--1067",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Metabotropic glutamate receptors

AU - Knopfel, T.

AU - Madge, D.

AU - Nicoletti, F.

PY - 1996

Y1 - 1996

N2 - Metabotropic glutamate (mGlu) receptors are becoming increasingly interesting as potential drug targets for the treatment of a variety of central nervous system (CNS) disorders including epilepsy and chronic and acute neurodegeneration. In contrast to the ionotropic glutamate (iGlu) receptors of the N-methyl-D-aspartate (NMDA), 2-amino-3-[5-methyl-3-hydroxyisoxazol-4-yl]propionic acid (AMPA) and kainate types that form ion channels, mGlu receptors couple to G-proteins and modulate a variety of membrane enzymes and ion channels. The eight mGlu receptor subtypes revealed to date by molecular cloning exhibit not only distinct pharmacological properties, but also different functions in the brain. This article describes the potential disease targets of compounds acting at the various mGlu receptor subtypes, and the development of such compounds by reviewing both the primary and patent literature.

AB - Metabotropic glutamate (mGlu) receptors are becoming increasingly interesting as potential drug targets for the treatment of a variety of central nervous system (CNS) disorders including epilepsy and chronic and acute neurodegeneration. In contrast to the ionotropic glutamate (iGlu) receptors of the N-methyl-D-aspartate (NMDA), 2-amino-3-[5-methyl-3-hydroxyisoxazol-4-yl]propionic acid (AMPA) and kainate types that form ion channels, mGlu receptors couple to G-proteins and modulate a variety of membrane enzymes and ion channels. The eight mGlu receptor subtypes revealed to date by molecular cloning exhibit not only distinct pharmacological properties, but also different functions in the brain. This article describes the potential disease targets of compounds acting at the various mGlu receptor subtypes, and the development of such compounds by reviewing both the primary and patent literature.

KW - central nervous system

KW - epilepsy

KW - G-protein coupled receptors

KW - metabotropic glutamate receptors

KW - neurodegeneration

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=0029837655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029837655&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1061

EP - 1067

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 10

ER -